Revenue segments as reported by the company.

U.S. Healthcare Solutions

International Healthcare Solutions

Pharmaceutical Distribution Services

Other

Intersegment eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, and administrative

Depreciation and amortization

Employee severance, litigation, and other

Goodwill impairment

Impairment of assets

Acquisition, integration, and restructuring expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cencora Inc

CoreSite Realty Corporation owns, develops, and operates data centers in certain data center markets in the United States, including Los Angeles, the San Francisco Bay and Northern Virginia areas, Chicago, and New York City. Its customer base consists of enterprise customers, communications service providers, media and content companies, government agencies, and educational institutions.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Cencora Inc (COR) excels in Q3, eyes growth through strategic partnerships

Cencora's Q3 performance reflects strong growth and strategic positioning in the healthcare industry. Leveraging its leadership in specialty services, the company aims to capitalize on opportunities through partnerships and customer-centric strategies while addressing challenges in managing key financial factors.

Cencora Inc posts robust fiscal 2024 results, eyes strategic expansion

Cencora Inc's Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and concerns about future challenges. The company's focus on expanding into new specialties and managing potential headwinds demonstrates a proactive approach to growth and risk management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment focuses on the distribution of specialty, brand-name, and generic pharmaceuticals. The International Healthcare Solutions segment includes pharmaceutical wholesale, related operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Amgen

Centene

Catalent

Gilead Sciences

Medtronic

Merck

Moderna

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on January 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice Presi.

Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release

American Airlines

Alaska Air Group

Avnet

Cleveland-Cliffs

We believe that stocks like American Airlines (AAL), Alaska Air Group (ALK), Cencora (COR), Cleveland-Cliffs (CLF) and Avnet (AVT) should be on an investor's watchlist.

5 Broker-Favored Stocks to Keep an Eye on in the Current Year

We have increased our price objective on Cencora to $226/share for the next 6-12 months. The company has exhibited continued earnings growth with minimal capital recycling and strategic use of leverage. COR has attractive economic characteristics and is trading at 16x forward earnings.

Cencora: Continued Economic Value On The Table Across All Investment Horizons

Investors are optimistic about Cencora's (COR) strength in the U.S. Healthcare Solutions business.

Cencora (COR) Hits 52-Week High: What's Aiding the Stock?

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Reasons to Retain Cencora (COR) Stock in Your Portfolio for Now

ABM Industries

Cardinal Health

We believe that stocks like American Airlines (AAL), ABM Industries (ABM), Cardinal Health (CAH), Cleveland-Cliffs (CLF) and Cencora (COR) should be on an investor's watchlist.

5 Broker-Favorite Stocks to Keep an Eye on as 2024 Approaches

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?

McKesson

Medical distributors are seeing increased demand for certain medicines. Drugs for weight loss made by Novo Nordisk and Eli Lilly are what's driving growth.

This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks

BOSTON , Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation. Under the agreement, Cencora will distribute the Sapphiros GoToKnow™ COVID-19 Antigen Rapid Tests to pharmacies across the United States.

Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement

BioNTech SE

Biotechnology is a booming industry recently focused on synthetic biology, biomanufacturing and gene editing. Biotech is seen as the key to the future, as it has the potential to cure diseases and save many lives.

3 Biotech Stocks You'll Regret Not Buying Soon: November 2023

NIKE

Agilent Technologies

Automatic Data Processing

American Equity Investment Life

Assurant

Atmos Energy

Becton, Dickinson and Co.

CubeSmart

Emerson Electric

Evergy Inc

Huntington Ingalls Industries

Hormel Foods

Lancaster Colony

Matthews International

McCormick

Motorola Solutions

Nelnet

Royal Gold

Roper Technologies

Snap-on

Spire

York Water

Investors were rewarded with 10%+ dividend increases from Snap-on Tools and ADP in the first half of November. Other companies that rewarded investors in the first two weeks of the month were Emerson, which extended its dividend growth streak to 67 years, and utilities Atmos and Evergy. The second half of the month will bring dividend increases from Nike, Merck, Hormel and Agilent, among others.

Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of November

Walgreens

Drugstore chain Walgreens Boots Alliance Inc. WBA, -2.62% on Thursday said it had sold shares of drug distributor Cencora Inc. COR, +0.02% for approximately $424 million. Walgreens also entered into a share repurchase by Cencora, formerly known as AmerisourceBergen, for proceeds of roughly $250 million.

Walgreens sells shares of drug distributor Cencora

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (the “Company”) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) (“Cencora”) common stock pursuant to variable prepaid forward transactions executed in reliance on Rule 144 under the Securities Act of 1933, as amended, for current proceeds of approximately $424 million and, depending on the stock price at the time, potentially additional proceeds at maturity. In addition, and subject to the closin.

Walgreens Boots Alliance Sells Shares of Cencora, Inc. for $674 Million of Initial Proceeds

A federal judge on Monday pared back a U.S. government lawsuit accusing drug distributor Cencora , formerly called AmerisourceBergen, of fueling the nation's deadly opioid epidemic by failing to report hundreds of thousands of suspicious orders of prescription painkillers.

Judge trims US lawsuit accusing Cencora of fueling opioid epidemic

Cencora, Inc. (COR) Q4 2023 Earnings Call Transcript

Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.

Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales

Drug distributor Cencora reported a fourth-quarter profit on Thursday that beat analysts' estimates as strong demand for costly specialty medicines helped offset a decline in COVID-related drug sales.

Cencora beats quarterly profit estimates on specialty drug demand

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. Revenue increased 9.9 percent to $262.2 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.72 for the September quarter of fiscal 2023, compared to $1.40 in the prior year qu.

Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results

Besides Wall Street's top -and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.

Exploring Analyst Estimates for Cencora (COR) Q4 Earnings, Beyond Revenue and EPS

Asbury Automotive Group

AMC Entertainment

Greenbrier Companies

Gap Inc

We believe that investors should keep a close watch on stocks like The Greenbrier Companies (GBX), AMC Entertainment (AMC), The Gap (GPS), Asbury Automotive (ABG) and Cencora (COR).

5 Broker-Loved Stocks to Watch in an Uncertain Scenario

Here's Why You Should Add Cencora (COR) to Your Portfolio Now

Cencora, Inc. (formerly AmerisourceBergen Corporation) has seen a 13% increase in stock price since my January publication. The company reported strong Q3 financials, with 11% YoY revenue growth and a positive outlook for FY'23. Market-implied expectations may be overly discounting COR's ability to compound intrinsic value over the coming periods.

Cencora: New Name, Same Old Economic Leverage, Reiterate Buy

Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Cencora (COR) a Solid Growth Stock? 3 Reasons to Think "Yes"

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Offi.

Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release

News for Cencora Inc Stock (COR)